UFP Technologies Inc. filings document operating results and material events for its medical-device contract development and manufacturing business. Form 8-K reports furnish quarterly and annual earnings releases, non-GAAP financial measures, Regulation FD investor presentation materials, material definitive agreements with strategic medical customers, cybersecurity incident disclosures, and executive succession and compensation arrangements.
Proxy filings cover board elections, executive compensation, equity awards, pay-versus-performance disclosure, and shareholder voting matters. These records frame the company's governance, capital and incentive structure, customer-contract disclosures, and public reporting obligations as a Nasdaq-listed operating company.
UFP Technologies, Inc. disclosed that its General Counsel, Secretary, and Senior Vice President of Human Resources, Christopher P. Litterio, plans to retire from the company after a transition period. The filing indicates a planned leadership change in the company’s legal and human resources functions rather than an immediate departure.
UFP Technologies director Daniel C. Croteau reported an open-market sale of 2,864 shares of Common Stock at $221.71 per share. The transaction involved non-derivative common stock and left him with 855 shares held directly following the sale.
UFP Technologies director Daniel C. Croteau exercised stock options to acquire 2,864 shares of common stock at $22.02 per share. Following the transaction, he directly holds 3,719 shares of UFP Technologies common stock. This filing reflects a derivative exercise rather than an open-market purchase or sale.
UFP Technologies reported solid first-quarter 2026 results with modest growth and continued strength in its medical business. Net sales rose to $154.2 million from $148.1 million, driven by 5.9% higher sales to medical customers, especially in robotic surgery, patient surfaces, and interventional and surgical products. Non-medical revenue declined 15%.
Gross margin edged up to 28.8%, supported by efficiencies in robotic surgery. Net income increased slightly to $17.5 million, or $2.24 diluted EPS, compared with $17.2 million and $2.21 a year earlier. Two major customers accounted for 24.8% and 22.1% of net sales, underscoring meaningful customer concentration.
Operating cash flow was $3.2 million, as higher receivables and inventory absorbed cash despite strong earnings. Cash stood at $20.0 million, and total debt under the company’s $275 million credit facility was $137.6 million at a roughly 5.0% average interest rate, with all covenants met.
Management highlighted reduced tariff impacts and expects future refunds via vendor credits after recent U.S. court decisions. A February 2026 cyber incident did not materially affect systems or results, though the company cautions that future cybersecurity issues could pose risks.
UFP Technologies reported modestly higher results for the first quarter ended March 31, 2026. Net sales reached $154.2 million, up 4.1% from $148.1 million a year earlier, while net income rose 1.8% to $17.5 million.
GAAP diluted EPS was $2.24 and adjusted diluted EPS was $2.48, compared with $2.21 and $2.47 in 2025. Medical market sales grew 5.9% to $143.4 million, but non-medical sales fell 15.0% to $10.8 million, reflecting the company’s focus on MedTech.
Gross margin edged up to 28.8%, while SG&A increased to $21.0 million, or 13.6% of sales. Operating income was $23.4 million, and adjusted EBITDA improved to $31.0 million. Management highlighted growth in robotic surgery and patient support segments and plans to add two new facilities in the Dominican Republic to meet forecasted demand.
UFP Technologies, Inc. has called a virtual annual meeting for June 4, 2026 at 10:00 a.m. Eastern, where shareholders can vote online using a 16‑digit control number. The agenda includes electing seven directors for one‑year terms, an advisory vote on executive pay, and ratifying Grant Thornton LLP as independent auditor for 2026.
The proxy details a planned leadership transition: long‑time CEO R. Jeffrey Bailly will retire as Chief Executive Officer effective June 4, 2026 and, if re‑elected, become Executive Chairman, while President Mitchell C. Rock will become Chief Executive Officer. As of April 10, 2026, 7,736,939 shares of common stock were outstanding and entitled to one vote per share. The filing also highlights majority‑independent board and committees, stock ownership guidelines, an executive compensation clawback policy, prohibition on hedging and pledging company stock, and a pay program that combines salary, performance‑based cash bonuses, and time‑ and performance‑based restricted stock units tied to adjusted operating income targets.
Congress Asset Management filed a Schedule 13G reporting beneficial ownership of 5.4% of UFP Technologies Inc. common stock as of 03/31/2026. The filing shows 416,762 shares held with sole voting and dispositive power.
UFP Technologies Inc ownership filing shows The Vanguard Group reporting no beneficial ownership of Common Stock following an internal realignment.
The filing states Vanguard disaggregated certain subsidiaries and business divisions and will report holdings separately in reliance on SEC Release No. 34-39538; the reported amount beneficially owned is 0 shares (0%).